Biosimilars

What it is

Biosimilars are biologic medicines shown to be highly similar to an approved reference biologic, with no clinically meaningful differences in safety, purity, or effectiveness. The key fact is that a biosimilar is not an exact copy in the way a generic tablet is, because biologics are large, complex molecules made in living cells. Instead, regulators require strong evidence that any small differences do not change how the medicine works in patients.

Biologics include medicines such as monoclonal antibodies, growth factors, insulin products, and other proteins used in cancer, autoimmune disease, and inflammatory conditions. In oncology, biosimilars are commonly discussed for drugs such as trastuzumab, bevacizumab, rituximab, pegfilgrastim, and filgrastim. Their main purpose is to expand access to effective biologic treatment while maintaining regulatory standards for quality, safety, and efficacy.

A simple comparison is:

Type	Made from	Compared with	Goal
Generic drug	Chemical synthesis	Brand-name small-molecule drug	Same active ingredient
Biosimilar	Living cells	Reference biologic	Highly similar, no clinically meaningful differences

In India, biosimilars are especially relevant because cancer biologics can be expensive, and lower-cost alternatives may improve access. India has its own regulatory pathway for similar biologics through the Central Drugs Standard Control Organisation (CDSCO) and Department of Biotechnology guidance.

How it works

A biosimilar works through the same biological target and expected clinical mechanism as its reference product. For example, a trastuzumab biosimilar is designed to bind the HER2 receptor in the same clinically relevant way as reference trastuzumab, and a bevacizumab biosimilar is designed to target vascular endothelial growth factor, or VEGF, like the originator product.

Because biologics are produced in living systems, there is natural batch-to-batch variability even within the original reference product over time. For that reason, biosimilar development focuses on a totality of evidence approach rather than proving the drug all over again from the beginning. This usually includes:

1. Analytical studies: detailed comparison of structure, purity, binding, and function.
2. Nonclinical studies: selected laboratory or animal data when needed.
3. Clinical pharmacology: comparison of how the drug behaves in the body and its biological effects.
4. Clinical confirmation: studies to confirm no clinically meaningful differences in efficacy, safety, and immunogenicity.

Immunogenicity matters because protein drugs can trigger anti-drug antibodies in some patients. A biosimilar must show that this risk is not meaningfully different from the reference biologic.

Evidence and uses

Biosimilars are used for the same or closely aligned indications as their reference biologics, depending on the regulator's approval. In cancer care, they may be used to treat the cancer itself, such as HER2-positive breast cancer with trastuzumab, or to support treatment, such as preventing chemotherapy-related neutropenia with filgrastim or pegfilgrastim.

Regulatory reviews and physician guidance consistently state that approved biosimilars should match the reference product in clinically meaningful outcomes. The evidence base usually starts with very sensitive laboratory comparisons, then moves to focused human studies. This is different from a new drug programme, where the aim is to establish benefit from scratch.

Important terms patients may hear include:

Term	Meaning
Reference product	The original approved biologic used for comparison
Biosimilar	Highly similar version with no clinically meaningful differences
Interchangeability	A separate legal or regulatory designation in some countries, not all
Extrapolation	Approval for additional indications based on the full evidence package

Extrapolation often causes confusion. It means a biosimilar may be approved for more than one use of the reference product even if it was not tested in a separate phase 3 trial for every disease. Regulators may allow this when the mechanism of action, pharmacology, immunogenicity, and other evidence support that decision. This is a scientific and regulatory judgment, not a shortcut without data.

Evidence from reviews and clinical experience suggests that switching from a reference biologic to an approved biosimilar is generally safe and effective for many products. Still, policies on substitution and interchangeability differ by country. The 2026 scoping review of WHO regions found substantial variation in how biosimilars are defined and classified across jurisdictions, which helps explain why patient information can sound different from one country to another.

In India, biosimilars have been available for years in several therapeutic areas, including oncology. Access, naming, pharmacovigilance, and hospital procurement practices can vary across institutions, so patients may receive either the originator biologic or a biosimilar depending on availability, cost, and clinician choice.

Safety and interactions

The side effects of a biosimilar are expected to be the same as those of its reference biologic because the active clinical effect is intended to be the same. For example, an infusion reaction, infection risk, low blood counts, hypertension, or heart-related monitoring needs depend on the specific biologic class, not on the fact that it is a biosimilar.

Key safety points:

• Do not assume all biosimilars are interchangeable in every setting. Rules differ by regulator and hospital policy.
• Keep the exact brand name and batch number when possible, especially if you have a side effect. This helps pharmacovigilance.
• Do not switch, stop, or substitute on your own. Decisions should be made with the treating oncologist or prescribing specialist.
• Interactions depend on the biologic itself. For example, some biologics should not be combined with live vaccines or certain immunosuppressive regimens without medical advice.

For patients with cancer, the practical safety issue is usually not whether a medicine is a biosimilar, but whether it is the right biologic for the disease, dose schedule, and treatment setting. If you have had a prior severe infusion reaction, loss of response, or a suspected immune-mediated adverse effect, tell your clinician exactly which product you received.

When to see a clinician

Speak with your oncologist, specialist, or oncology pharmacist if:

• you are told your biologic is being changed to a biosimilar
• you want to know whether the approved use is the same as the originator's use in your condition
• you develop a new infusion reaction, rash, fever, breathing problem, or swelling after treatment
• you are worried about cost, insurance, or hospital availability of the originator versus biosimilar
• you are pregnant, breastfeeding, or planning vaccination while on biologic therapy

Patients often benefit from asking for the brand name, generic name, and reason for the switch. In cancer care, this can reduce confusion when treatment is given across different hospitals or day-care infusion centres.

Limitations and open questions

Biosimilars are well established scientifically, but some issues remain unsettled across countries and health systems. One is terminology: not all regulators use the same definitions for biosimilarity, interchangeability, or substitution. Another is communication, because patients may hear that a biosimilar is "similar" and wrongly assume it is lower quality.

Evidence is strongest for products that have gone through modern, stringent regulatory review with detailed analytical comparison and post-marketing monitoring. Questions can still arise about naming conventions, automatic substitution rules, and how best to track adverse events in routine practice. Long-term real-world data continue to grow, especially for repeated switching and for use across multiple indications.

For patients and families, the most useful bottom line is this: an approved biosimilar is expected to perform like its reference biologic in clinically meaningful ways, but product choice and switching should still be guided by the treating clinician and local regulatory standards.